Ginkgo Bioworks (NYSE:DNA) Trading 8.8% Higher – Here’s Why

Posted by Lauren Steadman on Feb 14th, 2025

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report)’s stock price was up 8.8% during mid-day trading on Friday . The company traded as high as $14.58 and last traded at $14.74. Approximately 625,008 shares were traded during mid-day trading, a decline of 59% from the average daily volume of 1,532,414 shares. The stock had previously closed at $13.55.

Ginkgo Bioworks Trading Up 10.7 %

The company has a market capitalization of $861.97 million, a PE ratio of -1.15 and a beta of 1.16. The stock has a 50-day moving average of $11.12.

Hedge Funds Weigh In On Ginkgo Bioworks

Hedge funds and other institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its stake in shares of Ginkgo Bioworks by 4.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 82,815 shares of the company’s stock valued at $814,000 after acquiring an additional 3,152 shares during the period. Marshall Wace LLP purchased a new position in Ginkgo Bioworks in the fourth quarter valued at about $665,000. Jump Financial LLC acquired a new position in shares of Ginkgo Bioworks during the fourth quarter worth about $505,000. Barclays PLC boosted its position in shares of Ginkgo Bioworks by 353.6% in the fourth quarter. Barclays PLC now owns 54,166 shares of the company’s stock worth $531,000 after buying an additional 42,224 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Ginkgo Bioworks by 65.1% in the fourth quarter. Renaissance Technologies LLC now owns 114,654 shares of the company’s stock valued at $1,126,000 after buying an additional 45,200 shares in the last quarter. 78.63% of the stock is owned by institutional investors and hedge funds.

About Ginkgo Bioworks

(Get Free Report)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.